On February 8, 2024, in Paris, France, Owkin, a TechBio company focusing on combining human and artificial intelligence for precision medicine, announced its collaboration with Amazon Web Services (AWS) to revolutionize drug discovery, enhance clinical trials, and develop AI diagnostics. Leveraging AWS's global infrastructure and cloud platform, Owkin aims to improve data operations, achieve operational excellence, and advance research in precision medicine. This partnership will utilize AWS's high-performance computing and machine learning tools, including Amazon SageMaker for building, training, and deploying machine learning models, and Amazon Elastic Compute Cloud (Amazon EC2) UltraClusters powered by NVIDIA H100 Tensor Core GPUs for supercomputer-class performance. Owkin's use of AWS's infrastructure is intended to meet its petabyte-level storage needs, develop generative AI applications, and support the deployment of AI solutions across research partners, pathology labs, and biopharma. The collaboration also emphasizes data sovereignty, with Owkin maintaining full control over their data, supported by AWS's comprehensive compliance controls and 143 security standards and compliance certifications.